Latest / Community Health Media
T-DXd in HER2+ Breast Cancer with Drs. Ruta Rao & Irene Kang
How is T-DXd changing the treatment landscape for HER2-positive breast cancer?
Drs. Ruta Rao and Irene Kang discuss the evolving role of trastuzumab deruxtecan (T-DXd) across HER2-positive breast cancer, from first-line metastatic disease to neoadjuvant and adjuvant treatment.
They examine data from DESTINY-Breast09, DESTINY-Breast05, and DESTINY-Breast11, along with emerging maintenance strategies from PATINA and HER2CLIMB-05. The conversation also explores how these findings are influencing treatment selection, duration, sequencing, toxicity management, and individualized patient care…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.